この製品に関するご意見・ご照会・お問合せはこちら

【Featured Product】Full-length CD20 with complete epitopes

Target epitopes of anti-CD20 monoclonal antibodies

In view of the differences in the binding epitopes of multiple anti-CD20 monoclonal antibodies, it is obvious that antigens with the characteristics of complete epitopes are important for the development of antibody drugs.

ACROBiosystems has built multiple technology platforms to develop and produce full-length CD20 to facilitate the anti-CD20 drug R&D. 

Advantages of full-length CD20 proteins

• Expressed by HEK293: post-translational modification and proper protein folding

• Native conformation and complete antibody binding epitopes

• Suitable for immunization/antibody screening/ELISA/SPR/BLI/FACS

High bioactivity and affinity verified by binding to Rituximab and Ofatumumab

Assay Data

Immobilized Rituximab at 2 μg/mL (100 μL/well) can bind Human CD20 Full Length, His Tag (Cat. No. CD0-H52H1) with a linear range of 1-63 ng/mL.

Immobilized Ofatumumab at 2 μg/mL (100 μL/well) can bind Human CD20 Full Length, His Tag, HEK293 (SPR verified) (Cat. No. CD0-H52H3) with a linear range of 0.4-6 ng/mL (in presence of DDM and CHS).

>> Learn more about full-length CD20 proteins and verification data with free protocols

>> Learn more about full-length multi-pass transmembrane proteins and technology platforms